bioMérieux S.A. (FRA:EYWN)

Market Cap	12.57B
Revenue (ttm)	4.12B
Net Income (ttm)	377.90M
Shares Out	n/a
EPS (ttm)	3.17
PE Ratio	33.27
Forward PE	21.89
Dividend	0.90 (0.86%)
Ex-Dividend Date	Jun 9, 2025

Volume	100
Average Volume	31
Open	105.10
Previous Close	107.70
Day's Range	105.10 - 105.10
52-Week Range	96.25 - 130.60
Beta	n/a
RSI	36.22
Earnings Date	Oct 30, 2025

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EYWN

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.